OSCR
Oscar Health, Inc.
OSCR has the edge over TLSI overall, supported by stronger fundamentals and lower modeled downside.
TLSI
TriSalus Life Sciences, Inc.
TLSI offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
TLSI Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Unavailable |
TLSI's revenue is currently stable, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
TLSI PE Valuation
TLSI has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
TLSI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect TLSI's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over TLSI in the latest year-over-year earnings comparison.
TLSI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2025 | -$1.16 | +$6.21 |
TLSI is still losing money, but far less than before: $0.50 per share over the past year, against $7.37 at its worst in mid-2024.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over TLSI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over TLSI on profitability, with a higher operating margin.
TLSI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $12.9M | +11% |
| Q2 2026 | $11.4M | +1.7% |
| Q1 2026 | $8.9M | -2.9% |
| Q4 2025 | $13.2M | +60% |
| Q3 2025 | $11.6M | +57% |
| Q2 2025 | $11.2M | +52% |
| Q1 2025 | $9.2M | +42% |
| Q4 2024 | $8.3M | +44% |
TLSI's revenue is growing: $13M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -60% | +18 points |
| Q2 2026 | -86% | -21 points |
| Q1 2026 | -95% | -15 points |
| Q4 2025 | -25% | +67 points |
| Q3 2025 | -78% | +41 points |
| Q2 2025 | -65% | +46 points |
| Q1 2025 | -80% | +101 points |
| Q4 2024 | -92% | +155 points |
TLSI's operating margin was −60% last quarter, up 18 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over TLSI on cash generation, producing positive trailing cash flow while its opponent burns cash.
TLSI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5.4M | -$1.4M |
| Q2 2026 | -$10.2M | -$3M |
| Q1 2026 | -$6.6M | -$1.4M |
| Q4 2025 | -$2.5M | +$3.2M |
| Q3 2025 | -$3.9M | +$7.1M |
| Q2 2025 | -$7.2M | +$6.3M |
| Q1 2025 | -$5.3M | +$5.7M |
| Q4 2024 | -$5.8M | +$3.5M |
TLSI has burned cash in almost every quarter: −$25M over the past year, against −$22M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over TLSI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
TLSI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +177K shares |
| 1 year | +105% | +29.9M shares |
TLSI has 58M diluted shares, up 105% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
TLSI Net Leverage
TLSI's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
TLSI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.3 | Neutral |
| Stochastic | 5.4 | Oversold |
TLSI's weekly RSI is 32 (neutral) and its Stochastic is 5 (oversold).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
TLSI PE vs Healthcare Sector
TLSI has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over TLSI on trend strength, trading above more of its moving averages.
TLSI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.68 | 32% below |
| 20 week MA | $4.35 | 42% below |
| 50 week MA | $4.63 | 46% below |
| 100 week MA | $4.86 | 48% below |
| 200 week MA | $6.25 | 60% below |
TLSI is in a downtrend: it's below all five of its weekly moving averages, and 60% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over TLSI on returns for 2026, with the stronger performance.
TLSI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $10.3 | $9.97 | -3.4% |
| 2022 | $9.97 | $10.0 | +0.6% |
| 2023 | $10.0 | $8.45 | -16% |
| 2024 | $8.45 | $4.84 | -43% |
| 2025 | $4.84 | $6.87 | +42% |
| 2026 YTD | $6.87 | $2.52 | -63% |
TLSI has finished lower in three of the last five years. It's down 63% so far in 2026.